0001770069-21-000001.txt : 20210310 0001770069-21-000001.hdr.sgml : 20210310 20210310164010 ACCESSION NUMBER: 0001770069-21-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210310 DATE AS OF CHANGE: 20210310 EFFECTIVENESS DATE: 20210310 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MapLight Therapeutics, Inc. CENTRAL INDEX KEY: 0001770069 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-391790 FILM NUMBER: 21730371 BUSINESS ADDRESS: STREET 1: 501 2ND STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: 919-641-8778 MAIL ADDRESS: STREET 1: 501 2ND STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 FORMER COMPANY: FORMER CONFORMED NAME: Alvarado Therapeutics, Inc. DATE OF NAME CHANGE: 20190307 D 1 primary_doc.xml X0708 D LIVE 0001770069 MapLight Therapeutics, Inc. 501 2ND STREET SAN FRANCISCO CA CALIFORNIA 94107 919-641-8778 DELAWARE Alvarado Therapeutics, Inc. Corporation true 2018 Christopher A Kroeger c/o MapLight Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 Executive Officer Director George Pavlov c/o MapLight Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 Director Robert Malenka c/o MapLight Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 Director James Lillie c/o MapLight Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 Executive Officer Peter A Bisgaard c/o MapLight Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 Director Jonathan Gillis c/o MapLight Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 Executive Officer Anatol Kreitzer c/o MapLight Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 Executive Officer Biotechnology Decline to Disclose 06b false 2021-02-23 false true true The underlying shares of common stock issuable upon conversion. false 0 59999999 29999999 30000000 false 2 0 0 0 false MapLight Therapeutics, Inc. /s/ Jonathan Gillis Jonathan Gillis Chief Financial Officer 2021-03-10